Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • UCB S.A. UNSP.ADR 1/2 News

    64,79 $ -0,72% -0,47 $
    In : 60,546 € | 24.04.24 21:45:14 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A14WZY
    ISIN: US9034801012
    US-Symbol: UCBJY
    Typ: Aktie

    UCB S.A. UNSP.ADR 1/2 News

    12.04.24 - PR Newswire
    UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
    UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting PR Newswire
    10.04.24 - PR Newswire
    UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
    UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa PR Newswire
    04.04.24 - PR Newswire
    FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
    FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-​bkzx) for Moderate-​to-Severe Hidradenitis Suppurativa and Additional 2mL Device ...
    09.03.24 - PR Newswire
    First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
    First Presentation of Year 4 BIMZELX® (bimekizumab-​bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-​to-Severe Plaque Psoriasis PR Newswire
    08.03.24 - PR Newswire
    BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
    BIMZELX® 48-Week Phase 3 Analyses in Moderate-​to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count PR Newswire
    28.02.24 - PR Newswire
    UCB on Growth Path for a Decade Plus
    UCB on Growth Path for a Decade Plus PR Newswire
    03.01.24 - PR Newswire
    ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
    ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-​Acetylcholine Receptor ...
    02.12.23 - PR Newswire
    UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
    UCB presents new data about the real-​world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting PR ...
    01.12.23 - PR Newswire
    UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
    UCB presents new data advancing patient-​focused scientific leadership at American Epilepsy Society Annual Meeting PR Newswire
    14.11.23 - PR Newswire
    UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
    UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-​to-Severe Plaque Psoriasis PR Newswire
    11.11.23 - PR Newswire
    Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
    Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF) PR Newswire
    10.11.23 - PR Newswire
    UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
    UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-​bkzx) in Ankylosing Spondylitis at ACR Convergence 2023 Long-term data on investigational bimekizumab in the ...
    01.11.23 - PR Newswire
    UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
    UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and ...
    31.10.23 - PR Newswire
    NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters
    NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters PR ...
    18.10.23 - PR Newswire
    BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
    BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-​to-Severe Plaque Psoriasis PR Newswire
    13.10.23 - PR Newswire
    UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023
    UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023 PR Newswire
    12.10.23 - PR Newswire
    Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
    Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa PR Newswire
    04.10.23 - PR Newswire
    UCB presents late-breaking posters at Child Neurology Society Meeting
    UCB presents late-​breaking posters at Child Neurology Society Meeting PR Newswire
    21.07.23 - PR Newswire
    UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
    UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-​noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-​acetylcholine receptor ...
    27.06.23 - PR Newswire
    UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis
    UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-​noli) for the treatment of adults with generalized myasthenia gravis PR Newswire

    Newssuche

    Videos

    newspaper
    24.04.24
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »